New therapeutic approaches in primary systemic AL amyloidosis.
Primary systemic AL (amyloid light-chain) amyloidosis is a plasma cell disorder in which depositions of amyloid light-chain protein cause progressive organ failure. The prognosis of primary amyloidosis is generally poor, with a median survival of 1-2 years. There is no available treatment which improves impaired organ function by induction of amyloid mobilization. Since amyloidosis is a dynamic process, measures that reduce the supply of the amyloid fibril precursor protein can result in a major regression of the deposits. Conventional-dose melphalan can prolong the median duration of survival from 8.5 to 18 months, but the clinical response rates with improvement of impaired organ function are low and the response is slow. Preliminary data suggest that VAD is effective in AL amyloidosis. Up-front high-dose chemotherapy with autologous peripheral blood stem cell transplantation can result in an improvement of the patient's clinical condition, but the treatment-related toxicity can be high, owing to impaired organ function. The use of VAD followed by high-dose chemotherapy is the concept of a German trial. The improvement of the patient's condition prior to high-dose chemotherapy by induction of a remission with VAD might reduce the transplantation-related morbidity and mortality in amyloidosis.
Sezer
O
O
Universitätsklinikum Charité, Campus Mitte, Department of Hematology/Oncology, Humboldt Universität, D-10098 Berlin, Germany. sezer@charite.de
Eucker
J
J
Schmid
P
P
Possinger
K
K
D000682:Amyloid; D000686:Amyloidosis / Q000188:drug therapy / Q000628:therapy*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use
D000682:Amyloid; D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan